SM
ACAD icon

Sabby Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Sabby Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-6,470
Closed -$18.7M – 257
2016
Q4 		$18.7M Buy
+6,470
New +$171K 1.09% 21
2016
Q3 		– Sell
-4,674
Closed -$15.2M – 309
2016
Q2 		$15.2M Buy
4,674
+2,834
+154% +$94.8K 0.79% 24
2016
Q1 		$5.14M Buy
1,840
+351
+24% +$7.65K 0.26% 41
2015
Q4 		$5.31M Buy
1,489
+51
+4% +$1.8K 0.29% 59
2015
Q3 		$4.75M Buy
1,438
+265
+23% +$11K 0.2% 87
2015
Q2 		$4.91M Buy
+1,173
New +$45.4K 0.18% 94
2015
Q1 		– Sell
-28,364
Closed -$90.1K – 285
2014
Q4 		$90.1K Buy
+28,364
New +$804K 2.84% 8
2014
Q3 		– Sell
-27,474
Closed -$62.1M – 256
2014
Q2 		$62.1M Buy
27,474
+787
+3% +$16.4K 2.66% 9
2014
Q1 		$64.9M Sell
26,687
-3,176
-11% -$80.3K 3.64% 6
2013
Q4 		$74.6M Buy
29,863
+21
+0.1% +$495 4.76% 3
2013
Q3 		$82M Buy
29,842
+4,660
+19% +$97.4K 5.33% 3
2013
Q2 		$45.7M Buy
+25,182
New +$347K 3.05% 8

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Sabby Management's ACAD Position: Q4 2020 in Review

Sabby Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2020, closing a stake of 99,921 shares — an estimated $4.12M sold.

Sabby Management first reported a position in ACAD in Q2 2013 and held it in 9 quarters. The position peaked at $14.6M in Q2 2013. 307 funds tracked by Wall St. Rank hold ACAD as of Q4 2020.

  • Sabby Management reported no remaining Acadia Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Sabby Management sold 99,921 Acadia Pharmaceuticals shares in Q4 2020, an estimated $4.12M.
  • Sabby Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 9 quarters.
  • Sabby Management's Acadia Pharmaceuticals position peaked at $14.6M in Q2 2013.
  • 307 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2020.

Based on Sabby Management's 13F filing for Q4 2020, filed 16 Feb 2021.